Depletes CoQ10. This medication is commonly used for Hypertension
Coenzyme Q10 (CoQ10) plays a vital role in cellular energy production. However, our ability to produce CoQ10 naturally declines with age, and dietary sources rarely provide therapeutic levels. Additionally, beta-blocker medications can further deplete CoQ10 stores. Therefore, individuals taking beta-blockers may benefit from CoQ10 supplementation.
Garrido-Maraver J, Cordero MD, Oropesa-Ávila M, Fernández Vega A, de la Mata M, Delgado Pavón A, de Miguel M, Pérez Calero C, Villanueva Paz M, Cotán D, Sánchez-Alcázar JA. Coenzyme q10 therapy. Mol Syndromol. 2014 Jul;5(3-4):187-97. Hamada M, Kazatain Y, Ochi T, et al. Correlation between serum CoQ10 level and myocardial contractility in hypertensive patients. In Biomedical and Clinical Aspects of Coenzyme Q, vol 4, ed. K Folkers, Y Yamamura. Amsterdam: Elsevier, 1984, 263-70. Sarter B. Coenzyme Q10 and cardiovascular disease: a review. J Cardiovasc Nurs. 2002 Jul;16(4):9-20. Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergice blockers of beta-receptors. Res Commun Chem Pathol Pharmacol. 1977 May;17(1):157-64.
50% Ubiquinone and 50% Ubiquinol — 50 mg
CoQ10 deficiency can present in infancy as a severe encephalomyopathy or multisystemic mitochondrial disease, with features such as hypotonia, developmental delay, intractable seizures, lactic acidosis, cardiomyopathy, and failure to thrive. Reports of infantile‑onset multisystem CoQ10 deficiency describe very early presentations, sometimes in the neonatal period, with rapid neurologic deterioration and involvement of brain, heart, kidney, and liver, and many affected children die in the first months or years of life despite intensive care. The important clinical point is that, although outcomes are often poor in the most severe cases, some infants and young children show neurologic improvement or stabilization when CoQ10 deficiency is recognized early and high‑dose CoQ10 supplementation is started promptly, which is why this diagnosis is considered a treatable cause of infantile encephalomyopathy
CoQ10 is a key mitochondrial antioxidant, and circulating levels are often reduced in people with chronic kidney disease and chronic heart failure, where deficiency is linked to greater oxidative stress and poorer organ function. In CKD cohorts, lower CoQ10 levels correlate with increased cardiovascular risk, and supplementation has been reported to improve markers such as proteinuria, mitochondrial function, and oxidative stress, with some studies suggesting better preservation of kidney function over time. In patients with chronic heart failure, trials such as Q-SYMBIO have shown that CoQ10 supplementation can improve cardiac function parameters and significantly reduce major adverse cardiovascular events, cardiovascular mortality, and heart‑failure–related hospitalizations.
CoQ10 deficiency has been identified as a potentially reversible cause of steroid‑resistant nephrotic syndrome and glomerular nephropathy, particularly in children and young adults with genetic defects in CoQ10 biosynthesis. In reported series, affected patients often present with heavy proteinuria and progressive kidney dysfunction that fail to respond to standard steroid therapy, but genetic testing sometimes reveals mutations in CoQ10‑related genes (such as COQ2, COQ6, or ADCK4). The encouraging part is that in a subset of these cases, early and sufficiently dosed CoQ10 supplementation has been associated with reduced proteinuria and stabilization or partial improvement of kidney function, making it an important, treatable consideration in otherwise unexplained steroid‑resistant nephrotic syndrome.
In some children and young adults, primary CoQ10 deficiency has been linked to hypertrophic cardiomyopathy (HCM), where the heart muscle becomes abnormally thick and stiff despite the absence of more common causes like longstanding hypertension. Case series and reports describe patients with genetically confirmed CoQ10 biosynthetic defects who develop HCM alongside other mitochondrial features such as exercise intolerance, muscle weakness, or neurologic symptoms, and cardiac imaging often shows concentric or asymmetric left ventricular hypertrophy. The hopeful aspect is that early recognition and CoQ10 supplementation have, in some documented cases, led to improved cardiac function or stabilization of wall thickness over time, making CoQ10 deficiency a particularly important and potentially treatable consideration in otherwise unexplained or familial‑appearing HCM.
CoQ10 deficiency is a recognized cause of progressive cerebellar ataxia with cerebellar atrophy, often beginning in childhood or early adulthood and frequently accompanied by seizures, peripheral neuropathy, and cognitive or psychiatric changes. Case series and larger cohorts show that many patients with primary CoQ10 deficiency have prominent cerebellar atrophy on MRI and mixed neurologic features, and in some reports seizures occurred in roughly one‑third of affected individuals. The hopeful aspect is that, unlike many hereditary ataxias, early and sustained CoQ10 supplementation has led to meaningful improvement or stabilization of gait, strength, and seizure control in a substantial subset of patients, which is why CoQ10 deficiency is emphasized as a treatable cause of cerebellar ataxia that should not be missed.
In some adolescents and adults, CoQ10 deficiency presents as an isolated mitochondrial myopathy with exercise intolerance, early fatigue, and proximal muscle weakness rather than a full multisystem syndrome. Muscle biopsies in these patients often show reduced CoQ10 content and ragged‑red fibers or other mitochondrial changes, even when brain, heart, and kidneys appear largely spared on standard evaluation. The encouraging piece is that many individuals with CoQ10‑deficient myopathy experience noticeable improvements in exercise capacity, muscle strength, and CK levels after several months of adequately dosed CoQ10 supplementation, highlighting the importance of recognizing this treatable cause of mitochondrial muscle disease early.
In the gums and supporting tissues around the teeth, low CoQ10 levels have been linked to worse periodontal inflammation and deeper pocketing, likely because CoQ10 is essential for local mitochondrial energy production and antioxidant defense. Small human studies have found that people with periodontitis often have reduced CoQ10 in gingival tissue or crevicular fluid, and that topical or oral CoQ10 used alongside standard scaling and root planing can modestly improve measures such as bleeding on probing and pocket depth. The practical implication is that maintaining adequate CoQ10 status may help support healthier periodontal tissues and could be a useful adjunctive strategy, particularly in individuals with chronic gum disease or high oxidative stress in the oral cavity.